POMDOCTOR Net Income From Continuing Ops from 2010 to 2026

POM Stock   0.24  0.01  4.35%   
POMDOCTOR LIMITED Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to about -45.1 M. During the period from 2010 to 2026, POMDOCTOR LIMITED Net Loss quarterly data regression pattern had range of 76.3 M and standard deviation of  28,491,951. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-43 M
Current Value
-45.1 M
Quarterly Volatility
28.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check POMDOCTOR LIMITED financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among POMDOCTOR LIMITED's main balance sheet or income statement drivers, such as Depreciation And Amortization of 147 K, Interest Expense of 14.2 M or Total Revenue of 374.2 M, as well as many indicators such as Price To Sales Ratio of 13.42, Dividend Yield of 0.0 or Days Sales Outstanding of 19.31. POMDOCTOR financial statements analysis is a perfect complement when working with POMDOCTOR LIMITED Valuation or Volatility modules.
  
Build AI portfolio with POMDOCTOR Stock
Check out the analysis of POMDOCTOR LIMITED Correlation against competitors.
Evaluating POMDOCTOR LIMITED's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into POMDOCTOR LIMITED American's fundamental strength.

Latest POMDOCTOR LIMITED's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of POMDOCTOR LIMITED American over the last few years. It is POMDOCTOR LIMITED's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in POMDOCTOR LIMITED's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

POMDOCTOR Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(78,612,826)
Coefficient Of Variation(36.24)
Mean Deviation24,803,322
Median(96,181,846)
Standard Deviation28,491,951
Sample Variance811.8T
Range76.3M
R-Value0.75
Mean Square Error373.8T
R-Squared0.57
Significance0.0005
Slope4,253,543
Total Sum of Squares12988.7T

POMDOCTOR Net Income From Continuing Ops History

2026-45.1 M
2025-43 M
2024-37.4 M
2023-36.9 M
2022-19.8 M

About POMDOCTOR LIMITED Financial Statements

POMDOCTOR LIMITED investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how POMDOCTOR Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-43 M-45.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether POMDOCTOR LIMITED is a strong investment it is important to analyze POMDOCTOR LIMITED's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact POMDOCTOR LIMITED's future performance. For an informed investment choice regarding POMDOCTOR Stock, refer to the following important reports:
Check out the analysis of POMDOCTOR LIMITED Correlation against competitors.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Pharmaceutical Retailers sector continue expanding? Could POMDOCTOR diversify its offerings? Factors like these will boost the valuation of POMDOCTOR LIMITED. Anticipated expansion of POMDOCTOR directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every POMDOCTOR LIMITED data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate POMDOCTOR LIMITED using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating POMDOCTOR LIMITED's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause POMDOCTOR LIMITED's market price to deviate significantly from intrinsic value.
It's important to distinguish between POMDOCTOR LIMITED's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding POMDOCTOR LIMITED should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, POMDOCTOR LIMITED's market price signifies the transaction level at which participants voluntarily complete trades.